Pradhan Mantri Bhartiya Janaushadhi Pariyojana

1. At a Glance

• PMBJP is a Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers) scheme providing generic medicines at 50-80% cheaper prices than branded equivalents through dedicated retail outlets called Jan Aushadhi Kendras (JAKs) [1].
• Flagship instrument of India's affordable-healthcare policy — directly links to GS-II (health governance, welfare schemes) and GS-III (public health economics).
• As of 30.06.2026, 20,149 JAKs are operational nationwide, with a product basket of 2,110 medicines + 315 surgicals/consumables/devices [S8 - user-supplied excerpt].
• Aspirants must track evolving numbers each year — PIB releases quarterly/annual updates making this a recurring Prelims-fact-update topic.

2. Why in the News

• Latest PIB release (28 July 2026) updated scheme statistics: 20,149 JAKs opened till 30.06.2026; FY2025-26 sales of medicines worth ₹2,252.19 crore (MRP); FY2026-27 sales of ₹474.40 crore till 30.06.2026 [7].
• Preceded by PIB update (June/July 2025) reporting 16,912 JAKs opened till 30.06.2025, with a target of 25,000 JAKs by March 2027 [4].
• 8th Janaushadhi Diwas (around 7 March 2025) saw Kendra owners honoured for scheme outreach [5].

3. Background & Evolution

• Scheme originally launched in November 2008 as "Jan Aushadhi Campaign" by Department of Pharmaceuticals with Central Pharma Public Sector Undertakings (PSUs) [1].
• Rebranded in 2016 as Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) to expand scope [1].
• 7 March declared "Jan Aushadhi Diwas" at PM Narendra Modi's initiative, celebrated annually to boost awareness of generic medicines; 2025 theme: "जन औषधि: दाम कम, दवाई उत्तम" [S1, S6].
• Milestone trajectory: 15,000 JAKs (28.02.2025) → 15,057 JAKs (28.02.2025, PIB note) → 16,912 JAKs (30.06.2025) → 20,149 JAKs (30.06.2026) [S3, S4, S8].
• FY2024-25: sales crossed ₹1,000 crore by 20 October 2024, indicating accelerating scheme uptake [1].

4. Core Static Facts

Item	Detail
Implementing agency	Bureau of Pharma PSUs of India (BPPI), under Department of Pharmaceuticals
Nodal Ministry	Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals [7]
Launch year	November 2008; rebranded 2016 [1]
Retail outlet name	Jan Aushadhi Kendra (JAK) / Pradhan Mantri Bhartiya Janaushadhi Kendra (PMBJK) [1]
JAKs opened (30.06.2026)	20,149 [7]
Target	25,000 JAKs by March 2027 [4]
Product basket	2,110 medicines + 315 surgicals/consumables/devices [7]
Price differential	50-80% cheaper than branded medicines [7]
FY2025-26 sales (MRP)	₹2,252.19 crore [7]
FY2026-27 sales till 30.06.2026 (MRP)	₹474.40 crore [7]
Annual awareness day	Jan Aushadhi Diwas — 7 March [6]

5. Multi-Dimensional Analysis

Economic

• Reduces out-of-pocket health expenditure for households, a key driver of poverty in India given high OOP share in health spending.
• Generates entrepreneurship opportunities — JAKs run by individual entrepreneurs, unemployed pharmacists, and NGOs under incentive-linked models.

Social

• Improves access to affordable medicines for rural/semi-urban and low-income populations, advancing health equity.
• Directly supports elderly and chronic-disease patients (cardiovascular, anti-diabetic, anti-cancer categories) who bear recurring drug costs [7].

Governance/Administrative

• Implementation relies on decentralized retail network (JAKs) requiring consistent supply-chain and quality-control coordination by BPPI.
• Scaling target (25,000 by March 2027) tests administrative capacity for outlet licensing, drug procurement, and last-mile distribution [4].

Scientific/Technological

• Expanding product basket (now 2,110 medicines) reflects incorporation of newer therapeutic categories (anti-cancer, nutraceuticals) [7].

6. Recent Developments (last 12-18 months)

• 28 July 2026: PIB update — 20,149 JAKs; FY2025-26 sales ₹2,252.19 crore; FY2026-27 sales ₹474.40 crore till 30.06.2026 [7].
• 30 June 2025: 16,912 JAKs operational; 25,000-JAK target by March 2027 reaffirmed [4].
• 28 February 2025: 15,057 (per PIB note) / ~15,000 JAKs opened [S2, S3].
• March 2025: 8th Jan Aushadhi Diwas week-long celebrations (1-7 March 2025); Kendra owners honoured; theme "जन औषधि: दाम कम, दवाई उत्तम" [S5, S6].
• October 2024: Cumulative FY2024-25 sales crossed ₹1,000 crore (till 20 October 2024) [1].

7. Prelims Hooks

• PMBJP launched in November 2008; rebranded as PMBJP in 2016 [1].
• Implementing body: Bureau of Pharma PSUs of India (BPPI) under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (NOT Ministry of Health) [7].
• 7 March = Jan Aushadhi Diwas, first observed 2019 (initiative of PM Modi) [6].
• JAKs opened stood at 20,149 as on 30.06.2026 [7].
• Target: 25,000 JAKs by March 2027 [4].
• Product basket: 2,110 medicines + 315 surgicals/consumables/devices covering cardiovascular, anti-cancer, anti-diabetic, anti-infective, anti-allergic, gastro-intestinal, and nutraceutical categories [7].
• Price advantage: generic medicines 50-80% cheaper than branded equivalents [7].
• FY2025-26 total scheme sales (MRP): ₹2,252.19 crore [7].
• FY2024-25 sales crossed ₹1,000 crore by 20 October 2024 [1].
• 2025 Jan Aushadhi Diwas theme: "जन औषधि: दाम कम, दवाई उत्तम" [6].
• Retail outlets are officially termed Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJK) [1].

8. Mains Relevance

• GS-II: Government policies and interventions for development in health sector; Welfare schemes for vulnerable sections.
• GS-III: Issues relating to health infrastructure, indigenous pharma sector, generic drugs vs. branded drugs debate.
• Possible question stems:
• "Discuss the role of Pradhan Mantri Bhartiya Janaushadhi Pariyojana in reducing out-of-pocket health expenditure in India. What are the bottlenecks in its last-mile implementation?"
• "Generic medicines are often perceived as inferior to branded drugs despite bioequivalence. Critically examine this perception in the context of PMBJP's objectives."
• "Evaluate the administrative and supply-chain challenges in scaling Jan Aushadhi Kendras to the 2027 target."

9. Related Topics to Study Next

• Ayushman Bharat / PM-JAY — complementary health-financing scheme; compare financing vs. supply-side (PMBJP) interventions.
• National Health Policy 2017 — broader policy framework PMBJP operates under.
• Drug Price Control Order (DPCO) / NPPA — regulatory mechanism for medicine pricing, contrasts with PMBJP's market-based affordability approach.
• Generic vs. branded drugs debate — bioequivalence, quality assurance (WHO-GMP certification of PMBJP suppliers).
• Out-of-pocket health expenditure in India — NSSO/NITI Aayog data context.
• Pharma PSUs (IDPL, HAL, Bengal Chemicals) — origin institutions tied to BPPI's supply base.
• Ease of Doing Business for pharmacists/entrepreneurs — JAK ownership incentive schemes.

10. Common Errors / Trap Areas

• Confusing nodal ministry — PMBJP is under Ministry of Chemicals & Fertilizers (Dept. of Pharmaceuticals), NOT Ministry of Health & Family Welfare.
• Mixing up launch year (2008) with rebranding year (2016) — original scheme predates the "Pradhan Mantri" naming.
• Confusing Jan Aushadhi Diwas (7 March) with other health observance days (e.g., World Health Day - 7 April).
• Misremembering JAK numeric targets — these change annually in PIB releases; always verify against the latest press release date rather than citing outdated figures.
• Confusing implementing agency BPPI (Bureau of Pharma PSUs of India) with NPPA (National Pharmaceutical Pricing Authority), which is a separate regulatory body.